PT  - JOURNAL ARTICLE
AU  - Taylor, Steve M
AU  - Korwa, Sarah
AU  - Wu, Angie
AU  - Green, Cynthia L
AU  - Freedman, Betsy
AU  - Clapp, Sheila
AU  - Kirui, Joseph Kipkoech
AU  - O’Meara, Wendy P
AU  - Njuguna, Festus M
TI  - Monthly sulfadoxine/pyrimethamine-amodiaquine or dihydroartemisinin-piperaquine as malaria chemoprevention in young Kenyan children with sickle cell anemia: A randomized controlled trial
AID  - 10.1101/2022.08.02.22278335
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.08.02.22278335
4099  - http://medrxiv.org/content/early/2022/08/03/2022.08.02.22278335.short
4100  - http://medrxiv.org/content/early/2022/08/03/2022.08.02.22278335.full
AB  - Background Children with sickle cell anemia in areas of Africa with endemic malaria transmission are commonly prescribed malaria chemoprevention. The comparative efficacy of prevention regimens is largely unknown.Methods and Findings We enrolled Kenyan children aged 1-10 years with HbSS in a randomized, open-label trial conducted between January 23, 2018, and December 15, 2020, in Homa Bay, Kenya. Children were assigned 1:1:1 to daily Proguanil (the standard of care), monthly sulfadoxine/pyrimethamine-amodiaquine (SP-AQ), or monthly dihydroartemisinin/piperaquine (DP). The primary outcome was the cumulative incidence of clinical malaria at 12 months and the main secondary outcome was the cumulative incidence of painful events. Negative-binomial models were used to estimate incidence rate ratios (IRRs) per patient-year (PPY) at risk relative to Proguanil. The primary analytic population was the As-Treated Population. 246 children were randomized to daily Proguanil (n=81), monthly SP-AQ (n=83), or monthly DP (n=82). Overall, 53.3% (n=131) were boys and the mean age was 4.6 ± 2.5 years. The clinical malaria incidence was 0.04 episodes/PPY; relative to the daily Proguanil group, incidence rates were not significantly different in the monthly SP-AQ (IRR: 3.05, 95% confidence interval [CI]: 0.36–26.14; p=0.39) and DP (IRR: 1.36, 95% CI: 0.21–8.85; p=0.90) groups. Among secondary outcomes, relative to the daily Proguanil group, the incidence of painful events was not significantly different in the monthly SP-AQ and DP groups, while monthly DP reduced the rate of dactylitis (IRR: 0.47; 95% CI: 0.23–0.96; p=0.038). The incidence of P. falciparum infection relative to daily Proguanil was similar in the monthly SP-AQ group (IRR 0.46; 95% CI: 0.17—1.20; p=0.13) but reduced with monthly DP (IRR 0.21; 9 5% CI: 0.08—0.56; p=0.002). Serious adverse events were common and distributed between groups, though more children died receiving monthly SP-AQ (n=7) than Proguanil (2) or DP (1). Study limitations include the unexpectedly limited transmission of P. falciparum in the study setting, the high use of hydroxyurea, and the enhanced supportive care for trial participants, which may limit generalizability to higher-transmission settings where routine sickle-cell care is more limited.Conclusions Despite limited malaria transmission, monthly malaria chemoprevention with dihydroartemisinin-piperaquine reduced dactylitis and P. falciparum parasitization in Kenyan children with sickle cell anemia. Pragmatic studies of chemoprevention in higher malaria transmission settings are warranted.Trial registration clinicaltrials.gov: NCT03178643; Pan-African Clinical Trials Registry: PACTR201707002371165Author Summary Why was this study done?Sickle cell anemia (SCA) is a very common condition among children born in malaria-endemic areas of sub-Saharan Africa, but their supportive care regimens are poorly tailored to African settingsAmong the complications that children with SCA suffer are more severe outcomes owing to malaria, and therefore many African countries recommend various malaria preventive regimens for children with SCAIt is important to compare the efficacy and safety of these regimens in order to enhance the supportive care of African children with SCAWhat did the researchers do and find?In this study, 3 malaria chemoprevention regimens were compared among children under 10 years old with SCA at a single site in Homa Bay, KenyaChildren were randomly assigned to take daily Proguanil (which is the standard of care in Kenya), a monthly combination of sulfadoxine-pyrimethamine with amodiaquine (SP-AQ), or a monthly combination of dihydroartemisinin-piperaquine (DP), and then followed monthly for 12 monthsCases of malaria were very low among all 3 groups, but the combination of DP reduced the risk of being infected by P. falciparum parasites and of dactylitis, which is a common complication of SCADP was not associated with a higher rate of serious adverse events, but SP-AQ was associated with an unexpectedly higher rate of deaths that nearly reached statistical significanceWhat do these findings mean?Monthly DP may be an alternative to existing chemoprevention regimens for children with SCA owing to its safety, acceptability, and efficacy on hematologic eventsSP-AQ-associated mortality among children with SCA was unexpected and requires further evaluationFurther studies are needed to compare chemoprevention regimens on parasitologic and hematologic outcomes in areas of high P. falciparum transmission and delivered through routine SCA providersCompeting Interest StatementThe authors have declared no competing interest.Clinical TrialNCT03178643Funding StatementFunded by the NHLBI (R01HL134211 to SMT)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial protocol was approved by ethics committees of Moi University (0001907) and Duke University (Pro00077428), registered with clinicaltrials.gov (NCT03178643) and the Pan-African Clinical Trials Registry (PACTR201707002371165), and approved by the Kenyan Pharmacy and Poisons Board (ECCT/17/08/06).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData availability will be described in the final peer-reviewed manuscript